Thanks to some smart acquisitions, Boston Scientific is poised to debut everything from new asthma treatments to better implantable defibrillators, most of which won't move the needle until 2014, said Cramer, but that means the time to get into the stock is today. The company is also being helped by growth overseas, which has helped not only stabilize sales, but prompted management to declare that a small increase in revenue is possible in the second half of 2013.
Boston Scientific trades at just 12.5 times earnings, said Cramer, but with growth returning the stock could fetch a multiple to match that of its peers, which would value the stock a full 26% higher than it trades today. Shares have already had a big rally, Cramer admitted, but there's still definitely room to run.
Sometimes the sum of the parts are worth more than the whole, Cramer reminded viewers as he highlighted yet another company with hidden potential to bring out value, if only its management realized that breaking up would be the best thing for shareholders.
Cramer said that
(BAX - Get Report) could follow in the footsteps of
(ABT), which spun off its
(ABBV) division to huge gains.
Cramer explained that while Baxter is only up 9% so far this year, the company could do so much better if only it split its pharma business, which makes vaccines and other bioscience products, from its medical device business. He said combined as a single company, Baxter gets lost in the shuffle. But as two separate companies, analysts and investors would not only take notice, but also be able to assign full value to its parts.
Cramer reminded viewers that since its split, Abbott Labs is up 12%, while AbbVie is up 33%.
Johnson & Johnson
has rallied 42% over the past 12 months on the mere speculation that the company might split itself into four units.
So what's Baxter really worth? Cramer valued the pharma business at $56 a share and the company's medical devices at another $31 a share, giving the company a total value of $87.50 a share, or 19.5% higher than it trades today.
In the Lightning Round, Cramer was bullish on
Cramer was bearish on
In the "Mad Tweets" segment, Cramer responded to questions sent via Twitter to
remains very undervalued.
Cramer told another tweeter that investors should always reinvest their dividends. Always.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer opined on the horrendous IPO of
(FB - Get Report)
, a stock he owns for his charitable trust,
Action Alerts PLUS
. The first anniversary of that IPO is Saturday.
Cramer likened the Facebook IPO to a man-made forest fire, saying the IPO was a sad event for all those involved and especially those who love the markets as much as he does.
He said the combination of a greedy company, lopsided market information and an untrustworthy system led to institutional and inside investors cashing out just as millions of individual investors were buying in.
Since its IPO, Facebook has been able to re-engineer its mobile strategy, but it has never been able to regain the trust of Wall Street, said Cramer. He said Action Alerts PLUS owns the stock as a long-term speculation and has yet to be rewarded. Meanwhile, Cramer said he can't blame any investor for still not trusting the company.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,